Clinscience says Trialhub collaboration was key to speeding enrollment in a Phase IIb study examining a candidate therapy being developed to treat patients who have suffered in acute ischemic stroke (AIS).
The clinical research organization (CRO) shared details last week, claiming Trialhub’s technology – a “data intelligence platform” that automates metrics like average recruitment rate (ARR) and site experience assessment – helped it achieve the ambitious recruitment targets set by the sponsor.
The original brief for the clinical trial was to enroll 500 acute ischemic stroke (AIS) patients at 45 sites at pre-selected by the sponsor in four countries in Western Europe.
The sponsor also tasked Clinscience with identifying one additional country in Western Europe and five others in Central and Eastern Europe.
And according to Clinscience, Trialhub’s technology allowed it to quickly achieve these aims and confirm the availability of patients in countries selected by the sponsor.
The approach also allowed the contractor to identify additional the countries and potential trial sites that would best suit the client’s needs for the trial in question.
According to Trialhub the system aggregated real-time data from 80,000 sources, including a range of clinical trial registries and provided Clinscience with a list of sites experienced in the indication.
In addition, the firm said, the platform also crawled the internet in real-time to complete the set of data with the most current investigator contacts where they were missing from the registries.
Trialhub CEO Maya Zlatanova said, “Clinscience is one of the few CROs that started as a site management organization in Europe. This gives them an incredible advantage when planning а clinical trial because they know firsthand precisely how to select the right trial partners.
“I am glad we have the chance to support them in replicating this model globally and to complement their experience with accurate and real-time insights on the clinical research landscape.”